Aspirin protects low density lipoprotein from oxidative modification

Heart

Volumn 77, Issue 4, 1997, Pages 333-337

  Steer, Keith A ^a,b   Wallace, Tara M ^a   Bolton, Colin H ^a   Hartog, Martin ^a  

^a UNIVERSITY OF BRISTOL   (United Kingdom)

^b NORTHWICK PARK HOSPITAL   (United Kingdom)

Author keywords

Aspirin; Diminished LDL oxidation; Low density lipoproteins

Indexed keywords

ACETYLSALICYLIC ACID; LOW DENSITY LIPOPROTEIN;

ARTICLE; ATHEROSCLEROSIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; HUMAN; HUMAN EXPERIMENT; LIPOPROTEIN METABOLISM; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; OXIDATION; PRIORITY JOURNAL; VOLUNTEER;

EID: 0030916999     PISSN: 13556037     EISSN: None     Source Type: Journal    
DOI: 10.1136/hrt.77.4.333     Document Type: Article

References (34)

1. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, MacFarlane PW, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 1995;333:1301-7.
2. Lewis B. Lipid lowering in the secondary prevention of ischaemic heart disease. In: Laker MF, Neil A, Wood C, eds. Cholesterol lowering trials. London: Royal College of Physicians, 1993:45-57.
3. Piper J, Orrild L. Essential familial hypercholesterolemia and xanthomatosis: follow-up study of twelve Danish families. Am J Med 1956;21:34-46.
4. Steinberg D, Parthasarthy S, Carew TE, Khoo JC, Witzum JL. Beyond cholesterol: modifications of low density lipoprotein that increase its atherogenicity. N Engl J Med 1989;320:915-24.
5. Goldstein JL, Ho YK, Bass SK, Brown MS. Binding site on macrophage that mediates uptake and degradation of acetylated low density lipoprotein producing massive cholesterol deposition. Proc Natl Acad Sci USA 1979;76:333-7.
6. Brown MS, Goldstein JL. Lipoprotein metabolism in the macrophage: implications for cholesterol deposition in atherosclerosis. Annu Rev Biochem 1983;52:223-61.
7. Mahley RW, Innerarity TL, Weisgraher KH, Oh SY. Altered metabolism (in vivo and in vitro) of plasma lipoproteins after selective chemical modification of lysine residues of the apoproteins. J Clin Invest 1979;64:743-50.
8. Fogelman AM, Schechler I, Seager J, Hokom M, Child JS, Edwards PA. Malondialdehyde alteration of LDL leads to cholesteryl ester accumulation in human monocyte-macrophage. Proc Natl Acad Sci USA 1980;77:2214-18.
9. Pinckard RN, Hawkins FR, Farr RS. In vitro acetylation of plasma proteins, enzymes and DNA by aspirin. Nature 1968;219:68-9.
10. Hawkins D, Pinckard RN, Farr RS. Acetylation of human serum albumin by acetylsalicylic acid. Science 1968;160:780-1.
11. Hawkins D, Pinckard RN, Crawford IP, Farr RS. Structural changes induced by ingestion of acetylsalicylic acid. J Clin Invest 1969;48:536-42.
12. De Fura FG, Cerami A, Bunn HF, Lu YS, Peterson CM. The effect of aspirin on sickling and oxygen affinity of erythrocytes. Proc Natl Acad Sci USA 1973;70:3707-10.
13. Pihan G, Regillo C, Szaho S. Free radicals and lipid peroxidation in ethanol or aspirin-induced gastric mucosal injury. Dig Dis Sci 1987;32:1395-402.
14. Kirkova M, Ivancheva E, Russanov E. In vitro effects of aspirin on malondialdehyde formation and on activity of antioxidant and some metal-containing enzymes. Comp Biochem Physiol Pharmacol Toxicol Endocrinol 1994;108:145-52.
15. Kleinfeld HA, Hak-Lemmes HLM, Stalinhoef AFH, Demacker PNM. Improved measurement of low density lipoprotein susceptibility to copper-induced oxidation: application of a short procedure for isolating low density lipoprotein. Clin Chem 1992;38:2066-72.
16. Basu SK, Goldstein JL, Anderson RGW, Brown MS. Degradation of cationised low density lipoprotein and regulation of cholesterol metabolism in homozygous familial hypercholesterolaemia fibroblasts. Proc Natl Acad Sci USA 1976;73:3178-82.
17. Schwartz KB, Arey BJ, Tolmonk K, Mahanty S. Iron chelation as a possible mechanism for aspirin-induced malondialdehyde production by mouse liver microsomes and mitochondria. J Clin Invest 1988;81:165-70.
18. McGraham MC. Copper and aspirin treatment increase the antioxidant activity of plasma. Agents Actions 1990;31:39-64
19. Young IS, Trimble ER. Measurement of malondialdehyde in plasma by high performance liquid chromatography with fluorometric detection. Ann Clin Biochem 1991;28:504-8.
20. Arnaud J, Fortis I, Blachier S, Kia D, Favier A. HPLC analysis of vitamins A and beta-carotene in plasma and LDL. J Chromatogr 1991;572:103-16.
21. Iverson SA, Cawood P, Dormandy TL. A method for the measurement of a diene-conjugated derivative of linoleic acid, 18:2(9,11) in serum phospholipid, and possible origins. Ann Clin Biochem 1985;22:137-40.
22. Hessler JR, Robertson AL, Chisholm GM. LDL-induced cytotoxicity and its inhibition by HDL in human vascular smooth muscle and endothelial cells in culture. Atherosclerosis 1979;32:213-21.
23. Quinn MT, Parthasarathy S, Steinberg D. Endothelial cell-derived chemotactic activity for mouse peritoneal macrophages and the effects of modified forms of low density lipoprotein. Proc Natl Acad Sci USA 1985;82:5949-53.
24. Quinn MT, Parthasarathy S, Fong LG, Steinberg D. Oxidatively modified low density lipoproteins: a potential role in recruitment and retention of monocyte/ macrophages during atherogenesis. Proc Natl Acad Sci USA 1987;84:2995-8.
25. Esterbauer H, Dieber-Rotheneder M, Waeg G, Striegl G, Jurgens G. Biochemical, structural and functional properties of oxidised low-density lipoprotein. Chem Res Toxicol 1990;3:77-92.
26. Jurgens G, Hoff HF, Chisholm GM and Esterbauer H. Modification of human serum low-density lipoprotein by oxidation - characterization and pathophysiological implications. Chem Phys Lipids 1987;45:315-36.
27. Grootveld M, Halliwell B. Aromatic hydroxylation as a potential measure of hydroxyl-radical formation in vivo. Biochem J 1986;237:499-504.
28. Henrikson T, Mahoney EM, Steinberg D. Enhanced macrophage degradation of LDL previously incubated with cultured endothelial cells: recognition by receptors for acetylated LDL. Proc Natl Acad Sci USA 1981;78:6499-503.
29. Maziere C, Goldstein S, Moreau M, Maziere JC, Polanarski J. Aspirin induces alterations in low-density lipoprotein and decreases its catabolism by cultured human fibroblasts. FEBS Lett 1987;218:243-6.
30. Shamsuddin M, Mason RG, Ritchey JM, Honig GR, Klutz JM. Sites of acetylation of sickle cell haemoglobin by aspirin. Proc Natl Acad Sci USA 1971;71:4693-7.
31. Riley ML, Harding JJ. The reaction of malondialdehyde with lens protein and the protective effect of aspirin. Biochem Biophys Acta 1993;1158:107-12.
32. Kukreja RC, Kontas HA, Hess ML, Ellis ES. PGH synthase and lipoxygenase generates superoxide in the presence of NADH or NADPH. Circ Res 1986;59:612-19.
33. Manjula TS, Devi CS. Effect of aspirin on mitochondrial lipids in experimental myocardial infarction in rats. Biochem Mol Biol Int 1993;29:921-8.
34. Parthasarathy S, Khoo JC, Miller E, Barnett J, Witzum JL, Steinberg D. Low density lipoprotein rich in oleic acid is protected against oxidative modification; implications for dietary prevention of atherosclerosis. Proc Nat Acad Sci USA 1990;87:3894-8.